Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04829539 | Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment(BBT-II) | active not recruiting | Phase 3 | 400 | University of Rochester NCORP Research BaseOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03682289 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 83 | Rahul AggarwalOTHER | 1 |
| Apr 23, 2026 |
| clinicaltrials |
| NCT05951608 | A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 216 | AkesoINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07541001 | PRL3-Zumab in Patients With Advanced Solid Tumors(China Phase II) | active not recruiting | Phase 2 | 60 | Intra-IMMUSG Pte LtdINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04452955 | A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 51 | Intra-IMMUSG Pte LtdINDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01281176 | High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02041416 | Technology to Assess Vulnerable Older Adults With Cancer and Their Caregivers | active not recruiting | — | 100 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02517034 | Geriatric Assessment in Predicting Chemotherapy Toxicity and Vulnerabilities in Older Patients With Cancer | active not recruiting | N/A | 600 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02713269 | Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06544655 | A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 213 | Bristol-Myers SquibbINDUSTRY | 3 | Apr 17, 2026 | clinicaltrials |
| NCT06777316 | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 110 | Cogent Biosciences, Inc.INDUSTRY | 2 | Apr 17, 2026 | clinicaltrials |
| NCT00479128 | Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors | active not recruiting | Phase 1 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04592250 | Financial Toxicity in Cancer Patients | active not recruiting | — | 625 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05035667 | Patient Considerations of Social Media Account Management After Death | active not recruiting | — | 117 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05075759 | Testing Counseling and Mobile Health Interventions to Improve Physical Activity and Diet Quality in Survivors of Childhood Cancer(SALSA) | active not recruiting | N/A | 374 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06082960 | Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors | active not recruiting | Phase 1 | 45 | Gilead SciencesINDUSTRY | 3 | Apr 16, 2026 | clinicaltrials |
| NCT02387905 | Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases | active not recruiting | Phase 2 | 87 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04196972 | Telementoring Intervention (ECHO) for the Transformation of Professional Engagement, Practice Efficiency, and Community Building Through Team Meetings in Diagnostic Imaging Clinicians | active not recruiting | N/A | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04957615 | Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression | active not recruiting | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05071846 | MVX-ONCO-2 in Advanced Solid Tumors | active not recruiting | Phase 1 | 6 | University Hospital, GenevaOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05215769 | A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer | active not recruiting | N/A | 243 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04794699 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | active not recruiting | Phase 1 | 169 | IDEAYA BiosciencesINDUSTRY | 7 | Apr 9, 2026 | clinicaltrials |
| NCT03361436 | Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery | active not recruiting | Phase 1 | 15 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT00736749 | Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies | active not recruiting | — | 5,000 | Children's Oncology GroupNETWORK | 2 | Apr 6, 2026 | clinicaltrials |
| NCT02937272 | A Study of LY3200882 in Participants With Solid Tumors | active not recruiting | Phase 1 | 223 | Eli Lilly and CompanyINDUSTRY | 8 | Apr 3, 2026 | clinicaltrials |
| NCT03428802 | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | active not recruiting | Phase 2 | 21 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT00477958 | Assessment Tool for Older Patients With Cancer | active not recruiting | N/A | 1,062 | City of Hope Medical CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02503423 | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | active not recruiting | Phase 1 / Phase 2 | 253 | Taiho Oncology, Inc.INDUSTRY | 8 | Mar 20, 2026 | clinicaltrials |
| NCT04419532 | A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 40 | Daiichi SankyoINDUSTRY | 3 | Mar 20, 2026 | clinicaltrials |
| NCT02789228 | Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors(REST) | active not recruiting | Phase 1 | 28 | Children's National Research InstituteOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03347318 | Target Therapies Resistance Molecular Profiling in Patients With Neoplastic Disease(PROFILING) | active not recruiting | — | 2,500 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06357975 | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) | active not recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) | active not recruiting | Phase 1 | 30 | Cellectar Biosciences, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT04007744 | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 36 | Mayo ClinicOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04802174 | Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers | active not recruiting | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05364086 | An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study(DiRECT) | active not recruiting | — | 2,100 | University of Rochester NCORP Research BaseOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06057922 | A Study YL201 in Patients With Selected Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 990 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06367751 | Implementation of Liquid Biopsies During Routine Clinical Care in Patients With Advanced Malignancies (LIQPLAT)(LIQPLAT) | active not recruiting | N/A | 159 | University Hospital, Basel, SwitzerlandOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05781048 | A Phase I Clinical Study of the Safety, Tolerability,Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 56 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07450560 | Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET | active not recruiting | — | 30 | Shuanghu YuanOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | active not recruiting | Phase 1 | 12 | Baylor College of MedicineOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT03832569 | Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors | active not recruiting | Early Phase 1 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06715124 | QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations | active not recruiting | Phase 1 | 237 | Quanta TherapeuticsINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03833700 | A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) | active not recruiting | Phase 1 | 70 | Eisai Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04294628 | Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04735978 | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours | active not recruiting | Phase 1 | 123 | Replimune, Inc.INDUSTRY | 5 | Feb 27, 2026 | clinicaltrials |
| NCT05914376 | Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors | active not recruiting | Phase 1 | 24 | Hangzhou Converd Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07137195 | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) | active not recruiting | N/A | 47 | Ion Beam ApplicationsINDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03252938 | Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors(INSIGHT) | active not recruiting | Phase 1 | 83 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT04743466 | Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes | active not recruiting | — | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 24, 2026source: clinicaltrials